Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden - Report - MDSpire
Advertisement
Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden
Clinical Report: Real-World Assessment of Stapokibart's Effectiveness for Severe Olfactory Dysfunction
Overview
This study evaluates the efficacy of stapokibart in improving olfactory dysfunction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Significant olfactory improvements were observed as early as two weeks, with 52.5% of patients achieving normosmia by week 16.
Background
Olfactory dysfunction is a prevalent and debilitating symptom in patients with CRSwNP, affecting their quality of life. Traditional treatments have variable efficacy, highlighting the need for effective therapies. Stapokibart, an anti-IL-4 receptor monoclonal antibody, offers a novel approach to managing this condition.
Data Highlights
Outcome
Week 0
Week 16
P-value
Mean Objective Olfactory Score
3.05 ± 2.98
11.35 ± 3.73
P<0.0001
Nasal Polyp Score
4.03 ± 1.70
1.63 ± 1.61
P<0.001
Percentage Achieving Normosmia
-
52.5%
-
Key Findings
Stapokibart significantly reduced smell loss VAS by Week 2 (P<0.0001).
At Week 16, 52.5% of patients achieved normosmia.
Mean objective olfactory score improved from 3.05 to 11.35 (P<0.0001).
Nasal polyp score decreased from 4.03 to 1.63 (P<0.001).
Olfactory recovery was consistent across subgroups, regardless of baseline inflammatory markers.
Higher baseline polyp burden correlated with faster early improvement.
Clinical Implications
The findings suggest that stapokibart may be a valuable treatment option for patients with moderate-to-severe olfactory dysfunction due to CRSwNP. Clinicians should consider its use in patients who have not responded adequately to traditional therapies.
Conclusion
Stapokibart demonstrates rapid and sustained improvements in olfactory function in CRSwNP patients, with baseline characteristics influencing the speed of recovery but not the overall outcome.
